Synaptogenix (NASDAQ:SNPX) Shares to Reverse Split on Friday, April 5th

Synaptogenix, Inc. (NASDAQ:SNPX)’s stock is scheduled to reverse split on the morning of Friday, April 5th. The 1-25 reverse split was announced on Friday, April 5th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 5th.

Synaptogenix Price Performance

Shares of NASDAQ:SNPX remained flat at $0.18 during midday trading on Wednesday. The stock had a trading volume of 1,715,827 shares, compared to its average volume of 794,238. The firm has a market capitalization of $3.67 million, a price-to-earnings ratio of -0.17 and a beta of 1.33. The stock has a fifty day moving average of $0.19 and a 200 day moving average of $0.25. Synaptogenix has a 12 month low of $0.14 and a 12 month high of $1.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Prelude Capital Management LLC raised its stake in Synaptogenix by 13.9% during the 2nd quarter. Prelude Capital Management LLC now owns 14,364 shares of the company’s stock worth $75,000 after buying an additional 1,750 shares during the period. Renaissance Technologies LLC acquired a new position in Synaptogenix during the 2nd quarter worth approximately $83,000. Finally, Vanguard Group Inc. raised its stake in Synaptogenix by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 222,495 shares of the company’s stock worth $1,491,000 after buying an additional 5,659 shares during the period. 10.34% of the stock is owned by institutional investors and hedge funds.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.